Massachusetts House Bill H1206

Massachusetts 2025-2026 Regular Session

• Introduced: 2/27/25
• Refer: 2/27/25

Caption

Relative to epinephrine injectors

Impact

The proposed legislation is set to enhance the accessibility of epinephrine injectors for certain demographics, particularly those insured under the state’s group insurance scheme and Medicaid-managed care programs. By including coverage for epinephrine injectors in various health plans and limiting the costs associated with them, the bill could potentially increase the number of individuals who carry these critical devices. Given that these injectors are essential in life-threatening situations such as anaphylaxis, the enhancement of their insurance coverage is poised to have positive public health implications.

Summary

House Bill H1206 introduces provisions for the insurance coverage of epinephrine injectors within Massachusetts. The bill specifically mandates that various health insurance options, including those offered through state programs and private insurers, must cover the appropriate weight-based dosage of epinephrine injectors without subjecting them to higher deductibles, coinsurance, or out-of-pocket limits compared to other health benefits. This aims to ensure equitable access to life-saving medication for patients at risk for severe allergic reactions.

Contention

Some points of concern may arise regarding the financial impact on insurance providers, who could face increased costs as a result of mandated coverage. Insurers may argue that this requirement could lead to higher premiums, which could affect all policyholders. Additionally, discussions surrounding the appropriate reimbursement rates and implications for insurance market dynamics could become contentious as stakeholders analyze the balance between ensuring patient access and managing costs for insurers. The engagement of various healthcare stakeholders will be vital in addressing these concerns as the bill progresses through the legislative process.